Crisa

Indication
Indicated for mild-to-moderate atopic dermatitis

_
Administration
Topical Administration Apply thin layer of ointment to affected areas BID Wash hands after applying ointment, unless hands are being treated For topical use only; not for ophthalmic, oral, or intravaginal use

_
Adult Dose
Topical Atopic Dermatitis Indicated for mild-to-moderate atopic dermatitis Apply a thin layer topically to affected area(s) BID

_
Child Dose
Atopic Dermatitis Indicated for mild-to-moderate atopic dermatitis in children aged >2 yr <2 years: Safety and efficacy not established >2 years: Apply a thin layer topically to affected area(s) BID

_
Contraindication
History of hypersensitivity to crisaborole or any component of the formulation
Mode of Action
Phosphodiesterase (PDE)-4 inhibitor; results in increased intracellular cyclic adenosine monophosphate (cAMP) levels The specific mechanism by which crisaborole exerts its therapeutic action for atopic dermatitis is not well defined, although cAMP is thought to decrease the proinflammatory response (eg, cytokine release) associated with atopic dermatitis

_
Precaution
Hypersensitivity reactions reported, including contact urticaria; signs and symptoms may include severe pruritus, swelling, and erythema at the application site or at a distant site; discontinue immediately and initiate appropriate therapy if hypersensitivity suspected
Side Effect
1-10% Application site pain, burning, or stinging (4%) <1% Contact urticaria _ Pregnancy Category Note Pregnancy There are no available data in pregnant women to inform the drug-associated risk for major birth defects and miscarriage Crisaborole is systemically absorbed Lactation Unknown if distributed in human breast milk Crisaborole is systemically absorbed Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition _